⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1348007 | 0.97 | OPRL1 (0.35) | — | |
| Hydrochloric Acid SCHEMBL6207567 | 0.94 | OPRL1 (0.34) | — | |
| SCHEMBL19315560 | 0.89 | CDK5 (0.33) | — | |
| SCHEMBL18724673 | 0.87 | OPRL1 (0.31) | — | |
| SCHEMBL23863586 | 0.84 | OPRL1 (0.31) | — | |
| SCHEMBL20056361 | 0.84 | OPRL1 (0.31) | — | |
| SCHEMBL21869937 | 0.84 | OPRL1 (0.31) | — | |
| SCHEMBL2735541 | 0.81 | — | — | |
| SCHEMBL2735522 | 0.81 | — | — | |
| SCHEMBL29576884 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 339 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115490605-B | Polyaspartic acid ester and preparation method and application thereof | 浙江科技学院 | 2024-02-20 | — | — | CN | claimed |
| CN-115960328-A | Additives for 3D printing techniques | 赢创运营有限公司 | 2023-04-14 | — | — | CN | claimed |
| CN-115490605-A | Polyaspartic acid ester and preparation method and application thereof | 浙江科技学院 | 2022-12-20 | — | — | CN | claimed |
| US-20210238204-A1 | INDOLE COMPOUNDS, PROCESS FOR THE PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2021-08-05 | — | — | US | claimed |
| US-8916599-B2 | 1H-benz imidazole-5-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2014-12-23 | — | — | US | claimed |
| US-8598190-B2 | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-03 | — | — | US | claimed |
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | claimed |
| EP-2361252-A1 | 3H-IMIDAZO [4, 5-C]PYRIDINE-6-CARBOXAMIDES AS ANTI -INFLAMMATORY AGENTS | Boehringer Ingelheim International GmbH (DE) | 2011-08-31 | — | — | EP | claimed |
| US-7737180-B2 | Use of neboglamine (CR 2249) as an antipsychotic and neuroprotective | ROTTAPHARM S.P.A. (IT) | 2010-06-15 | — | — | US | claimed |
| EP-1755583-B1 | USE OF NEBOGLAMINE FOR THE TREATMENT OF SCHIZOPHRENIA | ROTTAPHARM SPA (IT) | 2010-04-14 | — | — | EP | claimed |
| WO-2010034796-A1 | 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | claimed |
| WO-2010034798-A1 | 3H-IMIDAZO [4, 5-C] PYRIDINE-6-CARBOXAMIDES AS ANTI -INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | claimed |
| US-20070249715-A1 | Use of Neboglamine (Cr 2249) as an Antipsychotic and Neuroprotective | ROTTAPHARM, S.P.A. (IT) | 2007-10-25 | — | — | US | claimed |
| EP-1755583-A1 | USE OF NEBOGLAMINE (CR 2249) AS AN ANTIPSYCHOTIC AND NEUROPROTECTIVE | ROTTAPHARM S.P.A. (IT) | 2007-02-28 | — | — | EP | claimed |
| EP-1121372-B1 | ADENINE DERIVATIVES | PFIZER LTD (GB) | 2006-06-28 | — | — | EP | claimed |
| WO-2005115373-A1 | USE OF NEBOGLAMINE (CR 2249) AS AN ANTIPSYCHOTIC AND NEUROPROTECTIVE | ROTTAPHARM S.P.A. (IT) | 2005-12-08 | — | — | WO | claimed |
| US-6326359-B1 | PURINE DERIVATIVES | PFIZER INC | 2001-12-04 | — | — | US | claimed |
| EP-1121372-A1 | ADENINE DERIVATIVES | Pfizer Limited (GB) | 2001-08-08 | — | — | EP | claimed |
| WO-2000023457-A1 | ADENINE DERIVATIVES | PFIZER LIMITED (GB) | 2000-04-27 | — | — | WO | claimed |
| CN-115835909-B | Cannabinoid receptor type 2 (CB 2) modulators and uses thereof | 泰昂治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12582641-B2 | Sulfur-containing compound based on glutarimide skeleton and application thereof | SHANGHAITECH UNIVERSITY (CN) | 2026-03-24 | — | — | US | disclosed |
| EP-4626870-A1 | NONCOVALENT KEAP1-NRF2 SMALL-MOLECULE INHIBITORS | University of Copenhagen (DK) | 2025-10-08 | — | — | EP | disclosed |
| WO-2025132542-A1 | MACROCYCLIC OREXIN AGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025124698-A1 | ARYL SULFONE AND SULFANONE DERIVATIVES AS OREXIN RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025077773-A1 | NOVEL TYPE I TOPOISOMERASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊维康医药有限责任公司 | 2025-04-17 | — | — | WO | disclosed |
| US-20250074901-A1 | NOVEL HETEROARYL COMPOUNDS | ANGELINI PHARMA S.P.A. (IT) | 2025-03-06 | — | — | US | disclosed |
| WO-2025049326-A1 | TRICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| EP-4472956-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | Bristol-Myers Squibb Company (US) | 2024-12-11 | — | — | EP | disclosed |
| US-12162848-B2 | Inhibitors of protein tyrosine phosphatase, compositions, and methods of use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-12-10 | — | — | US | disclosed |
| CN-118834587-A | Asparagus polyurea wood coating composition | 深圳飞扬骏研新材料股份有限公司 | 2024-10-25 | — | — | CN | disclosed |
| EP-4433453-A1 | NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS | Icagen, LLC (US) | 2024-09-25 | — | — | EP | disclosed |
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-19 | — | — | US | disclosed |
| CN-118660875-A | Protein tyrosine phosphatase inhibitors, compositions, and methods of use | 百时美施贵宝公司 | 2024-09-17 | — | — | CN | disclosed |
| CN-221693660-U | Reaction kettle for producing dimethylcyclohexylamine | 山东联创精细化学品有限公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-118496461-A | Polyurethane foam containing unmodified lignin | 通用汽车环球科技运作有限责任公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20240252504-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS INC (US) | 2024-08-01 | — | — | US | disclosed |
| CN-118184572-A | Preparation of novel HsClpP agonists and application thereof in anti-inflammatory and anti-tumor | 四川大学 | 2024-06-14 | — | — | CN | disclosed |
| WO-2024115641-A1 | NONCOVALENT KEAP1-NRF2 SMALL-MOLECULE INHIBITORS | UNIVERSITY OF COPENHAGEN (DK) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024098053-A1 | POLYMER-NUCLEIC ACID NANOPARTICLES FOR GENE EDITING | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20240124412-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-04-18 | — | — | US | disclosed |
| US-11957689-B2 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | TEON THERAPEUTICS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-11858931-B2 | Amino acid compounds with unbranched linkers and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230382925-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382925-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382925-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-11-30 | — | — | US | disclosed |
| US-11827638-B2 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-28 | — | — | US | disclosed |
| WO-2023212057-A1 | COMPOSITIONS OF KINETIC NANOPARTICLES CONTAINING NUCLEIC ACIDS, POLYCATIONS AND LIPIDS | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230322695-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY | 2023-10-12 | — | — | US | disclosed |
| US-20230322695-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY | 2023-10-12 | — | — | US | disclosed |
| US-20230322695-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY | 2023-10-12 | — | — | US | disclosed |
| CN-116783204-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-09-19 | — | — | CN | disclosed |
| EP-4225764-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11718633-B2 | Indole compounds, process for the preparation and use thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2023-08-08 | — | — | US | disclosed |
| WO-2023147531-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147531-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-07-20 | — | — | US | disclosed |
| US-11697804-B2 | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230174488-A1 | SARS-COV-2 INHIBITORS HAVING COVALENT MODIFICATIONS FOR TREATING CORONAVIRUS INFECTIONS | INSILICO MEDICINE IP LIMITED (HK) | 2023-06-08 | — | — | US | disclosed |
| WO-2023091554-A1 | NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS | ICAGEN, LLC (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023091554-A1 | NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS | ICAGEN, LLC (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230159517-A1 | CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2023081730-A1 | 4-HYDROXY-2-OXO-1,2-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CANNABINOID CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | TEON THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081730-A1 | 4-HYDROXY-2-OXO-1,2-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CANNABINOID CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | TEON THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230143502-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS, INC | 2023-05-11 | — | — | US | disclosed |
| US-20230143502-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS, INC | 2023-05-11 | — | — | US | disclosed |
| US-20230143502-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS, INC | 2023-05-11 | — | — | US | disclosed |
| US-11643397-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-05-09 | — | — | US | disclosed |
| CN-111606883-B | Sulfur-containing compound based on glutarimide skeleton and application thereof | 上海科技大学 | 2023-05-09 | — | — | CN | disclosed |
| WO-2023069708-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| CN-115960328-A | Additives for 3D printing techniques | 赢创运营有限公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-115835909-A | Cannabinoid receptor type 2 (CB 2) modulators and uses thereof | 泰昂治疗公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-4146345-A2 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | Teon Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| US-11564928-B1 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | TEON THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11564928-B1 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | TEON THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| CN-111148734-B | Pyrrole-2-formamide compound and preparation method and application thereof | 中国医学科学院药物研究所 | 2023-01-06 | — | — | CN | disclosed |
| US-20230002372-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-20230002372-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-20220396586-A1 | THIAZOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220396586-A1 | THIAZOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2022-12-15 | — | — | US | disclosed |
| EP-3555096-B1 | IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-23 | — | — | EP | disclosed |
| EP-4034108-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | The Global Alliance for TB Drug Development, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-4034106-A1 | THIAZOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | The Global Alliance for TB Drug Development, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| CN-114746090-A | Azaindole carboxamide compounds for the treatment of mycobacterial infections | 结核病药物开发全球联盟公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-114746089-A | Thiazolecarboxamide compounds and their use for the treatment of mycobacterial infections | 结核病药物开发全球联盟公司 | 2022-07-12 | — | — | CN | disclosed |
| US-20220143002-A1 | SULFUR-CONTAINING COMPOUND BASED ON GLUTARIMIDE SKELETON AND APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-05-12 | — | — | US | disclosed |
| EP-3515913-B1 | AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | NOVARTIS AG (CH) | 2022-05-11 | — | — | EP | disclosed |
| WO-2022076624-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| CN-109715629-B | Aza-indazole compounds for use in tendon and/or ligament injuries | 诺华股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-3932922-A1 | SULFUR-CONTAINING COMPOUND BASED ON GLUTARIMIDE SKELETON AND APPLICATION THEREOF | ShanghaiTech University (CN) | 2022-01-05 | — | — | EP | disclosed |
| US-11203595-B2 | Aza-indazole compounds for use in tendon and/or ligament injuries | NOVARTIS AG (CH) | 2021-12-21 | — | — | US | disclosed |
| WO-2021226206-A2 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021226206-A2 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| US-20210347740-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2021-11-11 | — | — | US | disclosed |
| US-20210238204-A1 | INDOLE COMPOUNDS, PROCESS FOR THE PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2021-08-05 | — | — | US | disclosed |
| US-20210206768-A1 | IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-08 | — | — | US | disclosed |
| US-20210188842-A1 | AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | NOVARTIS AG (CH) | 2021-06-24 | — | — | US | disclosed |
| EP-3260454-B1 | CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2021-06-09 | — | — | EP | disclosed |
| EP-3828174-A1 | PYRIDAZINONE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2021-06-02 | — | — | EP | disclosed |
| CN-105593224-B | Novel quinazolinones as bromodomain inhibitors | 恒元生物医药科技(苏州)有限公司 | 2021-05-25 | — | — | CN | disclosed |
| US-10981911-B2 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-20 | — | — | US | disclosed |
| WO-2021062316-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| WO-2021062316-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| WO-2021062318-A1 | THIAZOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| WO-2021062318-A1 | THIAZOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| WO-2021039961-A1 | RING-FUSED PYRAZOLE DERIVATIVE | 大日本住友製薬株式会社 | 2021-03-04 | — | — | WO | disclosed |
| US-20210032202-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTE FOR TROPICAL DISEASES PTE LTD. (SG) | 2021-02-04 | — | — | US | disclosed |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2020-11-05 | — | — | US | disclosed |
| US-20200330396-A1 | NONVIRAL GENE TRANSFER TO THE SUPRACHOROIDAL SPACE | THE JOHNS HOPKINS UNIVERSITY | 2020-10-22 | — | — | US | disclosed |
| EP-2857425-B1 | METHOD FOR PREPARING POLYMER AND POLYMER PREPARED THEREBY | LG CHEMICAL LTD (KR) | 2020-10-14 | — | — | EP | disclosed |
| WO-2020198145-A1 | GENE DELIVERY PARTICLES TO INDUCE TUMOR-DERIVED ANTIGEN PRESENTING CELLS | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-10-01 | — | — | WO | disclosed |
| US-10766894-B2 | Aza-indazole compounds for use in tendon and/or ligament injuries | NOVARTIS AG (CH) | 2020-09-08 | — | — | US | disclosed |
| CN-111606883-A | Sulfur-containing compound based on glutarimide framework and application thereof | 上海科技大学 | 2020-09-01 | — | — | CN | disclosed |
| WO-2020148619-A1 | NOVEL SUBSTITUTED SULFONYLUREA DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2020-07-23 | — | — | WO | disclosed |
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2020-05-21 | — | — | US | disclosed |
| CN-111148734-A | Pyrrole-2-formamide compound and preparation method and application thereof | 中国医学科学院药物研究所 | 2020-05-12 | — | — | CN | disclosed |
| US-20190322665-A1 | IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-24 | — | — | US | disclosed |
| EP-3555096-A1 | IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES | Janssen Pharmaceutica NV (BE) | 2019-10-23 | — | — | EP | disclosed |
| CN-110312719-A | Imidazopyrrolopyridines as JAK Family Kinase Inhibitors | 詹森药业有限公司 | 2019-10-08 | — | — | CN | disclosed |
| US-20190300522-A1 | AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2019-10-03 | — | — | US | disclosed |
| EP-2993194-B1 | MULTI-BLOCK COPOLYMER | LG CHEMICAL LTD (KR) | 2019-07-03 | — | — | EP | disclosed |
| US-10336711-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-07-02 | — | — | US | disclosed |
| CN-109715629-A | AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | 诺华股份有限公司 | 2019-05-03 | — | — | CN | disclosed |
| WO-2019070727-A2 | NONVIRAL GENE TRANSFER TO THE SUPRACHOROIDAL SPACE | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-04-11 | — | — | WO | disclosed |
| WO-2019042267-A1 | PYRROLE-2-FORMAMIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND APPLICATIONS THEREOF | 中国医学科学院药物研究所 | 2019-03-07 | — | — | WO | disclosed |
| EP-3027604-B1 | NOVEL QUINAZOLINONES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD (CA) | 2019-02-20 | — | — | EP | disclosed |
| US-20180305323-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2018-10-25 | — | — | US | disclosed |
| US-10035779-B2 | Prolyl hydroxylase inhibitors | GlaxoSmithKline, LLC (US) | 2018-07-31 | — | — | US | disclosed |
| WO-2018130174-A1 | PYRROLO[2,3-C]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | 江苏豪森药业集团有限公司 | 2018-07-19 | — | — | WO | disclosed |
| WO-2018112382-A1 | IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-21 | — | — | WO | disclosed |
| EP-3305789-A1 | NITROGEN-CONTAINING TRICYCLIC DERIVATIVE HAVING HIV REPLICATION INHIBITORY ACTIVITY | Shionogi & Co., Ltd. (JP) | 2018-04-11 | — | — | EP | disclosed |
| US-20180092924-A1 | NOVEL QUINAZOLINONES AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2018-04-05 | — | — | US | disclosed |
| EP-2684880-B1 | DISPIROPYRROLIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2018-02-28 | — | — | EP | disclosed |
| US-9884832-B2 | Inhibitors targeting drug-resistant influenza A | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884118-B2 | Multicomponent degradable cationic polymers | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884118-B2 | Multicomponent degradable cationic polymers | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-02-06 | — | — | US | disclosed |
| US-9855271-B2 | Quinazolinones as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2018-01-02 | — | — | US | disclosed |
| EP-3260454-A1 | CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2017-12-27 | — | — | EP | disclosed |
| EP-2892880-B1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2017-11-22 | — | — | EP | disclosed |
| EP-2037922-B9 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-3019493-B1 | MODIFIED BET-PROTEIN INHIBITING DIHYDROCHINOXALINONES AND DIHYDROPYRIDOPYRAZINONES | Bayer Pharma AG (DE) | 2017-06-14 | — | — | EP | disclosed |
| US-9663508-B2 | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663508-B2 | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| EP-2917185-B1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | EVOTEC INT GMBH (DE) | 2017-05-10 | — | — | EP | disclosed |
| CN-104603106-B | Indole carboxamide derivatives and uses thereof | 诺华股份有限公司 | 2017-05-10 | — | — | CN | disclosed |
| US-20170114029-A1 | TREATMENT OF CHAGAS DISEASE | SYNGENE INTERNATIONAL LIMITED (IN) | 2017-04-27 | — | — | US | disclosed |
| US-20170114029-A1 | TREATMENT OF CHAGAS DISEASE | SYNGENE INTERNATIONAL LIMITED (IN) | 2017-04-27 | — | — | US | disclosed |
| US-20170114029-A1 | TREATMENT OF CHAGAS DISEASE | SYNGENE INTERNATIONAL LIMITED (IN) | 2017-04-27 | — | — | US | disclosed |
| US-9611500-B2 | Method for detecting the presence of the viable cells in an endodontic sample | KINGS COLLEGE LONDON (GB) | 2017-04-04 | — | — | US | disclosed |
| EP-3144311-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVE HAVING HIV REPLICATION-INHIBITING EFFECT | Shionogi & Co., Ltd. (JP) | 2017-03-22 | — | — | EP | disclosed |
| WO-2017035060-A1 | INHIBITORS OF EZH2 | ELI LILLY AND COMPANY (US) | 2017-03-02 | — | — | WO | disclosed |
| EP-2945950-B1 | ISOMANNIDE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | SANOFI SA (FR) | 2017-03-01 | — | — | EP | disclosed |
| WO-2016194806-A1 | NITROGEN-CONTAINING TRICYCLIC DERIVATIVE HAVING HIV REPLICATION INHIBITORY ACTIVITY | 塩野義製薬株式会社 | 2016-12-08 | — | — | WO | disclosed |
| US-20160355477-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2016-12-08 | — | — | US | disclosed |
| US-20160355477-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2016-12-08 | — | — | US | disclosed |
| US-20160297772-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-10-13 | — | — | US | disclosed |
| US-9447039-B2 | Indole carboxamide derivatives and uses thereof | NOVARTIS AG (CH) | 2016-09-20 | — | — | US | disclosed |
| US-9447039-B2 | Indole carboxamide derivatives and uses thereof | NOVARTIS AG (CH) | 2016-09-20 | — | — | US | disclosed |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | One Amgen Center Drive (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | One Amgen Center Drive (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160193218-A1 | NOVEL QUINAZOLINONES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. (CA) | 2016-07-07 | — | — | US | disclosed |
| EP-3027604-A2 | NOVEL QUINAZOLINONES AS BROMODOMAIN INHIBITORS | Zenith Epigenetics Corp. (CA) | 2016-06-08 | — | — | EP | disclosed |
| CN-102516115-B | As the antagonist of Opioid Receptors or the new compound of inverse agonist | SMITHKLINE BEECHAN CORP. (US) | 2016-05-11 | — | — | CN | disclosed |
| US-9315697-B2 | Multi-block copolymer | LG CHEM, LTD. (KR) | 2016-04-19 | — | — | US | disclosed |
| EP-2993194-A1 | MULTI-BLOCK COPOLYMER | LG Chem, Ltd. (KR) | 2016-03-09 | — | — | EP | disclosed |
| WO-2015189595-A1 | TREATMENT OF CHAGAS DISEASE | UNIVERSITY OF DUNDEE (GB) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015189595-A1 | TREATMENT OF CHAGAS DISEASE | UNIVERSITY OF DUNDEE (GB) | 2015-12-17 | — | — | WO | disclosed |
| CN-105121487-A | Multiblock copolymer | LG CHEMICAL LTD | 2015-12-02 | — | — | CN | disclosed |
| US-20150315157-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-11-05 | — | — | US | disclosed |
| US-9090764-B2 | Polymer preparing method and polymer prepared by the same | LG CHEM, LTD. (KR) | 2015-07-28 | — | — | US | disclosed |
| EP-2892880-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2015-07-15 | — | — | EP | disclosed |
| US-20150191439-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-09 | — | — | US | disclosed |
| US-20150175539-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2015-06-25 | — | — | US | disclosed |
| US-20150175539-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2015-06-25 | — | — | US | disclosed |
| US-9040565-B2 | 1H-benzimidazole-5-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2015-05-26 | — | — | US | disclosed |
| CN-104603106-A | Indole carboxamide derivatives and uses thereof | NOVARTIS AG | 2015-05-06 | — | — | CN | disclosed |
| US-9006257-B2 | Bicyclic compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-04-14 | — | — | US | disclosed |
| EP-2857425-A1 | METHOD FOR PREPARING POLYMER AND POLYMER PREPARED THEREBY | LG Chem, Ltd. (KR) | 2015-04-08 | — | — | EP | disclosed |
| CN-102753538-B | Sultam derivatives | HOFFMANN LA ROCHE | 2015-04-08 | — | — | CN | disclosed |
| CN-104487468-A | Method for preparing polymer and polymer prepared thereby | LG CHEMICAL LTD | 2015-04-01 | — | — | CN | disclosed |
| US-8980903-B2 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors | AMGEN INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980903-B2 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors | AMGEN INC. (US) | 2015-03-17 | — | — | US | disclosed |
| EP-2504324-B1 | SULTAM DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-02-25 | — | — | EP | disclosed |
| US-20140375934-A1 | MULTI-BLOCK COPOLYMER | LG CHEM, LTD. (KR) | 2014-12-25 | — | — | US | disclosed |
| US-8916599-B2 | 1H-benz imidazole-5-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2014-12-23 | — | — | US | disclosed |
| US-20140350244-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | AMGEN INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140350244-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | AMGEN INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140336383-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC | 2014-10-30 | — | — | US | disclosed |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC | 2014-10-30 | — | — | US | disclosed |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC | 2014-10-30 | — | — | US | disclosed |
| US-8841312-B2 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors | AMGEN INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841312-B2 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors | AMGEN INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8822518-B2 | Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction | GLAXOSMITHKLINE LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822518-B2 | Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction | GLAXOSMITHKLINE LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822518-B2 | Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction | GLAXOSMITHKLINE LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-8815884-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-08-26 | — | — | US | disclosed |
| CN-103980151-A | Novel compounds as antagonists or inverse agonists at opioid receptors | SMITHKLINE BEECHAM CORP | 2014-08-13 | — | — | CN | disclosed |
| CN-101522614-B | Compounds as antagonists or inverse agonists of opioid receptors | SMITHKLINE BEECHAM CORP | 2014-06-25 | — | — | CN | disclosed |
| US-20140100255-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC (US) | 2014-04-10 | — | — | US | disclosed |
| WO-2014037900-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2014-03-13 | — | — | WO | disclosed |
| US-20140066573-A1 | POLYMER PREPARING METHOD AND POLYMER PREPARED BY THE SAME | LG CHEM, LTD. (KR) | 2014-03-06 | — | — | US | disclosed |
| US-20140024666-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-01-23 | — | — | US | disclosed |
| EP-2037922-B1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-01-22 | — | — | EP | disclosed |
| US-8633175-B2 | Compounds as antagonists or inverse agonists at opioid receptors | GLAXOSMITHKLINE LLC (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633175-B2 | Compounds as antagonists or inverse agonists at opioid receptors | GLAXOSMITHKLINE LLC (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633175-B2 | Compounds as antagonists or inverse agonists at opioid receptors | GLAXOSMITHKLINE LLC (US) | 2014-01-21 | — | — | US | disclosed |
| US-8623407-B2 | Gabapentin-containing solid compositions and process for preparing the same | PFIZER INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623407-B2 | Gabapentin-containing solid compositions and process for preparing the same | PFIZER INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8598190-B2 | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-03 | — | — | US | disclosed |
| US-8557834-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-10-15 | — | — | US | disclosed |
| WO-2013118071-A1 | BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-15 | — | — | WO | disclosed |
| US-20130210844-A1 | BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-15 | — | — | US | disclosed |
| WO-2013086131-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-06-13 | — | — | WO | disclosed |
| EP-2588467-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130085131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-04 | — | — | US | disclosed |
| CN-102186903-B | Batch process for preparing polyamides | BASF SE | 2013-03-27 | — | — | CN | disclosed |
| US-20130072487-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-03-21 | — | — | US | disclosed |
| EP-2240483-B1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2013-02-27 | — | — | EP | disclosed |
| US-8324208-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-12-04 | — | — | US | disclosed |
| US-8314250-B2 | Sultam derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2504324-A1 | SULTAM DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-03 | — | — | EP | disclosed |
| US-8278442-B2 | Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders | PROSIDION LIMITED (GB) | 2012-10-02 | — | — | US | disclosed |
| CN-102516115-A | Novel compounds as antagonists or inverse agonists at opioid receptors | SMITHKLINE BEECHAM CORP | 2012-06-27 | — | — | CN | disclosed |
| US-20120122930-A1 | 1H-Benzimidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-17 | — | — | US | disclosed |
| WO-2012003274-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-8063247-B2 | Bicyclic aryl and heteroaryl receptor modulators | PROSIDION LIMITED (GB) | 2011-11-22 | — | — | US | disclosed |
| US-8063247-B2 | Bicyclic aryl and heteroaryl receptor modulators | PROSIDION LIMITED (GB) | 2011-11-22 | — | — | US | disclosed |
| US-20110275656-A1 | 3H-Imidazo [4, 5-C] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | disclosed |
| CN-102186903-A | Batch process for preparing polyamides | BASF SE | 2011-09-14 | — | — | CN | disclosed |
| EP-2361252-A1 | 3H-IMIDAZO [4, 5-C]PYRIDINE-6-CARBOXAMIDES AS ANTI -INFLAMMATORY AGENTS | Boehringer Ingelheim International GmbH (DE) | 2011-08-31 | — | — | EP | disclosed |
| CN-102164922-A | 3H-imidazo [4,5-C ] pyridine-6-carboxamides as anti-inflammatory agents | BOEHRINGER INGELHEIM INT | 2011-08-24 | — | — | CN | disclosed |
| EP-2334664-A1 | 1H-BENZIMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | Boehringer Ingelheim International GmbH (DE) | 2011-06-22 | — | — | EP | disclosed |
| US-20110142796-A1 | Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors | AMGEN INC (US) | 2011-06-16 | — | — | US | disclosed |
| WO-2011064141-A1 | SULTAM DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-03 | — | — | WO | disclosed |
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110124686-A1 | SULTAM DERIVATIVES | ANDERSON KEVIN W | 2011-05-26 | — | — | US | disclosed |
| US-7939528-B2 | Heterocycle compounds | GLAXOSMITHKLINE LLC (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939528-B2 | Heterocycle compounds | GLAXOSMITHKLINE LLC (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939528-B2 | Heterocycle compounds | GLAXOSMITHKLINE LLC (US) | 2011-05-10 | — | — | US | disclosed |
| WO-2011050284-A1 | PYRAZOLYLPYRIDINE ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-04-28 | — | — | WO | disclosed |
| CN-101001920-B | Reactive hot-melt resin composition and reactive hot-melt adhesive | KONISHI CO LTD | 2011-01-12 | — | — | CN | disclosed |
| US-20100267780-A1 | BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS | PROSIDION LIMITED (GB) | 2010-10-21 | — | — | US | disclosed |
| US-20100267780-A1 | BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS | PROSIDION LIMITED (GB) | 2010-10-21 | — | — | US | disclosed |
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
| US-20100173886-A1 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100173886-A1 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100166819-A1 | Transforming Growth Factor Modulators | BIOGEN IDEC MA INC. A CORPORATION | 2010-07-01 | — | — | US | disclosed |
| US-20100166819-A1 | Transforming Growth Factor Modulators | BIOGEN IDEC MA INC. A CORPORATION | 2010-07-01 | — | — | US | disclosed |
| US-7737180-B2 | Use of neboglamine (CR 2249) as an antipsychotic and neuroprotective | ROTTAPHARM S.P.A. (IT) | 2010-06-15 | — | — | US | disclosed |
| US-20100113444-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-05-06 | — | — | US | disclosed |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | IGNAR DIANE MICHELE | 2010-05-06 | — | — | US | disclosed |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | IGNAR DIANE MICHELE | 2010-05-06 | — | — | US | disclosed |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | IGNAR DIANE MICHELE | 2010-05-06 | — | — | US | disclosed |
| US-20100105654-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-04-29 | — | — | US | disclosed |
| US-20100105654-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-04-29 | — | — | US | disclosed |
| US-20100105654-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-04-29 | — | — | US | disclosed |
| EP-1755583-B1 | USE OF NEBOGLAMINE FOR THE TREATMENT OF SCHIZOPHRENIA | ROTTAPHARM SPA (IT) | 2010-04-14 | — | — | EP | disclosed |
| WO-2010034796-A1 | 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010034797-A1 | 1H-BENZIMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010034798-A1 | 3H-IMIDAZO [4, 5-C] PYRIDINE-6-CARBOXAMIDES AS ANTI -INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| CN-100590149-C | Curable resin composition and moisture-curing adhesive composition | KONISHI CO LTD | 2010-02-17 | — | — | CN | disclosed |
| US-7625909-B2 | Substituted quinazolinone compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625909-B2 | Substituted quinazolinone compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625909-B2 | Substituted quinazolinone compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7598386-B2 | Sulphones which modulate the action of gamma-secretase | MERCK SHARP & DOHME LIMITED (GB) | 2009-10-06 | — | — | US | disclosed |
| US-7595344-B2 | Sulphones which modulate the action of gamma secretase | MERCK SHARP & DOHME LIMITED (GB) | 2009-09-29 | — | — | US | disclosed |
| CN-101522614-A | Novel compounds as antagonists or inverse agonists of opioid receptors | SMITHKLINE BEECHAM CORP (US) | 2009-09-02 | — | — | CN | disclosed |
| WO-2009085185-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | AMGEN INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090156677-A1 | Gabapentin-containing Solid Compositions and Process for Preparing the Same | PFIZER INC | 2009-06-18 | — | — | US | disclosed |
| US-20090156677-A1 | Gabapentin-containing Solid Compositions and Process for Preparing the Same | PFIZER INC | 2009-06-18 | — | — | US | disclosed |
| US-20090131419-A1 | Sulphones which modulate the action of gamma secretase | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| EP-2054383-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SmithKline Beecham Corporation (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-2037922-A2 | PROLYL HYDROXYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2009030962-A1 | BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS | PROSIDION LIMITED (GB) | 2009-03-12 | — | — | WO | disclosed |
| US-20090054431-A1 | NOVEL HETEROCYCLE COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-02-26 | — | — | US | disclosed |
| US-20090054431-A1 | NOVEL HETEROCYCLE COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-02-26 | — | — | US | disclosed |
| US-20090054431-A1 | NOVEL HETEROCYCLE COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-02-26 | — | — | US | disclosed |
| US-7476670-B2 | Purine derivatives, method for preparing, pharmaceutical compositions and novel use | AVENTIS PHARMA S.A. (FR) | 2009-01-13 | — | — | US | disclosed |
| EP-1431285-B1 | REVERSE HYDROXAMIC ACID DERIVATIVES | KAKEN PHARMA CO LTD (JP) | 2009-01-07 | — | — | EP | disclosed |
| WO-2008141799-A1 | OLIGOPHOSPHORAMIDATES | ROCHE DIAGNOSTICS GMBH (DE) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008142454-A1 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2008-11-27 | — | — | WO | disclosed |
| EP-1692143-B1 | TRICYCLIC INDOLE HYDROXYETHYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2008-11-12 | — | — | EP | disclosed |
| EP-1943226-A2 | PHENOL ETHERS AS MODULATORS OF THE OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2008063714-A1 | METABOLICALLY-STABILIZED INHIBITORS OF FATTY ACID AMIDE HYDROLASE | N.V. ORGANON (NL) | 2008-05-29 | — | — | WO | disclosed |
| US-20080119549-A1 | METABOLICALLY-STABILIZED INHIBITORS OF FATTY ACID AMIDE HYDROLASE | N.V. ORGANON (NL) | 2008-05-22 | — | — | US | disclosed |
| US-20080119549-A1 | METABOLICALLY-STABILIZED INHIBITORS OF FATTY ACID AMIDE HYDROLASE | N.V. ORGANON (NL) | 2008-05-22 | — | — | US | disclosed |
| US-7368453-B2 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368453-B2 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368453-B2 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080090849-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | AVENTIS PHARMA S.A. (FR) | 2008-04-17 | — | — | US | disclosed |
| EP-1903028-A1 | Conjugates of glutamate and NMDA receptor channel blockers without excito-toxic effects | Tschollar,, Werner (CH) | 2008-03-26 | — | — | EP | disclosed |
| WO-2008021849-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021849-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021851-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007150011-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
| US-7309719-B1 | Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid | WARNER LAMBERT COMPANY, LLC (US) | 2007-12-18 | — | — | US | disclosed |
| US-7309719-B1 | Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid | WARNER LAMBERT COMPANY, LLC (US) | 2007-12-18 | — | — | US | disclosed |
| US-20070249715-A1 | Use of Neboglamine (Cr 2249) as an Antipsychotic and Neuroprotective | ROTTAPHARM, S.P.A. (IT) | 2007-10-25 | — | — | US | disclosed |
| US-20070213329-A1 | Sulphones which modulate the action of gammasecretase | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2007-09-13 | — | — | US | disclosed |
| US-20070185140-A1 | Novel purine derivatives, method for preparing them, their application as medicinal products, pharmaceutical compositions and novel use | AVENTIS PHARMA S. A. (FR) | 2007-08-09 | — | — | US | disclosed |
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| CN-101001920-A | Reactive hot-melt resin composition and reactive hot-melt adhesive | KONISHI CO LTD (JP) | 2007-07-18 | — | — | CN | disclosed |
| WO-2007047397-A2 | PHENOL ETHERS AS MODULATORS OF THE OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047397-A2 | PHENOL ETHERS AS MODULATORS OF THE OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-26 | — | — | WO | disclosed |
| EP-1755583-A1 | USE OF NEBOGLAMINE (CR 2249) AS AN ANTIPSYCHOTIC AND NEUROPROTECTIVE | ROTTAPHARM S.P.A. (IT) | 2007-02-28 | — | — | EP | disclosed |
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| CN-1881094-A | Developing agent and image forming apparatus using the same | TOSHIBA TEC KK (JP) | 2006-12-20 | — | — | CN | disclosed |
| CN-1823139-A | Curable resin composition and moisture-curing adhesive composition | KONISHI CO LTD (JP) | 2006-08-23 | — | — | CN | disclosed |
| EP-1121372-B1 | ADENINE DERIVATIVES | PFIZER LTD (GB) | 2006-06-28 | — | — | EP | disclosed |
| CN-1735592-A | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LTD (GB) | 2006-02-15 | — | — | CN | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
| US-6992103-B2 | Benzamide derivatives, processes for their preparation, and their pharmaceutical use | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-01-31 | — | — | US | disclosed |
| WO-2005115373-A1 | USE OF NEBOGLAMINE (CR 2249) AS AN ANTIPSYCHOTIC AND NEUROPROTECTIVE | ROTTAPHARM S.P.A. (IT) | 2005-12-08 | — | — | WO | disclosed |
| EP-1587796-A1 | SATURATED QUINOXALINE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2005-10-26 | — | — | EP | disclosed |
| US-20050192297-A1 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION GLAXOSMITHKLINE | 2005-09-01 | — | — | US | disclosed |
| EP-1567488-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| US-20050085520-A1 | Benzamide derivatives, processes for their preparation, and their pharmaceutical use | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-04-21 | — | — | US | disclosed |
| US-20050059662-A1 | Substituted quinazolinone compounds | CHIRON CORPORATION | 2005-03-17 | — | — | US | disclosed |
| WO-2005016925-A1 | AZAQUINAZOLINE DERIVATIVES | PFIZER LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
| US-20050038047-A1 | Azaquinazoline derivatives | EDWARDS PAUL JOHN (GB) | 2005-02-17 | — | — | US | disclosed |
| US-20050004130-A1 | New metabotropic glutamate receptor compounds | ASTRAZENECA AND NPS PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
| EP-1448520-A1 | BENZAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 2004-08-25 | — | — | EP | disclosed |
| WO-2004069813-A1 | SATURATED QUINOXALINE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004050619-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
| WO-2003045913-A1 | BENZAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-06-05 | — | — | WO | disclosed |
| CN-1379666-A | Non-peptide GnRH agents, methods and intermediates for their preparation | AGOURON PHARMA (US) | 2002-11-13 | — | — | CN | disclosed |
| EP-0688312-B1 | NEW DERIVATIVES OF GLUTAMIC ACID, A METHOD OF PREPARING THEM, AND THEIR USE AS DRUGS FOR ENHANCING MEMORY AND LEARNING | ROTTA RESEARCH LAB (IT) | 1998-11-18 | — | — | EP | disclosed |
| US-5723494-A | Derivatives of glutamic and aspartic acids, a method of preparing them, and their use as drugs for enhancing memory and learning | ROTTA RESEARCH LABORATORIUM S.P.A. (IT) | 1998-03-03 | — | — | US | disclosed |
| EP-0705817-A1 | New cannamide derivatives and their use as allergy inhibitors | TSUMURA & CO. (JP) | 1996-04-10 | — | — | EP | disclosed |
| EP-0688312-A1 | NEW DERIVATIVES OF GLUTAMIC ACID, A METHOD OF PREPARING THEM, AND THEIR USE AS DRUGS FOR ENHANCING MEMORY AND LEARNING | ROTTA RESEARCH LABORATORIUM S.P.A. (IT) | 1995-12-27 | — | — | EP | disclosed |
| US-5438056-A | Anticholesterol agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-08-01 | — | — | US | disclosed |
| WO-1994020454-A1 | NEW DERIVATIVES OF GLUTAMIC AND ASPARTIC ACIDS, A METHOD OF PREPARING THEM, AND THEIR USE AS DRUGS FOR ENHANCING MEMORY AND LEARNING | ROTTA RESEARCH LABORATORIUM S.P.A. (IT) | 1994-09-15 | — | — | WO | disclosed |
| US-5344845-A | Methyl 4(4-acetoxy-3-methoxycinnamanide and salts as an immunosuppressive drug for allergic reactions | TSUMURA & CO. (JP) | 1994-09-06 | — | — | US | disclosed |
| EP-0535250-A1 | NOVEL COMPOUNDS AND USE THEREOF AS MEDICINE | TSUMURA & CO. (JP) | 1993-04-07 | — | — | EP | disclosed |
| EP-0535250-A1 | NOVEL COMPOUNDS AND USE THEREOF AS MEDICINE | TSUMURA & CO. (JP) | 1993-04-07 | — | — | EP | disclosed |